Yarrow Bioscience, Inc.

YARW Nasdaq SEC CIK 1566044
Follow Yarrow Bioscience Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Net income −$9.7M
EPS, diluted −$0.43
Operating cash flow −$90M
Operating income −$10.7M
Revenue by quarter
$121K
$84K
$202K
$69K
$86K
$97K
Q3 24 Q4 24 Q1 25 Q2 25 Q1 26 Q2 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income12 fiscal years
  • Revenue
  • Net income
−$75M−$50M−$25M$0$25MFY15FY17FY19FY21FY23FY25
Show the numbers
YearRevenueNet income
FY25$570K−$26.5M
FY24$501K−$39.8M
FY23$424K−$28.5M
FY22$477K−$23.2M
FY21$931K−$73.3M
FY20$21M-
FY19$443K-
FY18$3.6M-
FY17$4.6M−$29.1M
FY16$674K−$14.1M
FY15-−$4.6M
FY14--
MarginsShare of revenue
  • Gross margin
  • Operating margin
  • Net margin
−30000%−20000%−10000%0%10000%FY15FY17FY19FY21FY23FY25
Show the numbers
YearGross marginOperating marginNet margin
FY25-−5219.1%−4646.1%
FY24-−8710%−7950.9%
FY23-−6900.5%−6710.4%
FY22-−7189.7%−4865.8%
FY21-−4179.5%−7876.4%
FY2093.4%−1203%-
FY19100%−21641.8%-
FY18100%−2083.2%-
FY17-−645.9%−634.6%
FY16-−2126.4%−2087.2%
FY15---
FY14---
Free cash flowOperating cash flow minus capital expenditure
−$150M−$100M−$50M$0FY15FY17FY19FY21FY23FY25
Show the numbers
YearFree cash flow
FY25−$33.1M
FY24−$34.1M
FY23−$25.3M
FY22-
FY21−$56.4M
FY20−$137.2M
FY19−$74.5M
FY18−$69.2M
FY17−$28.2M
FY16−$2.3M
FY15−$4.2M
FY14-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Yarrow Bioscience
  • Healthcare median
−8000%−6000%−4000%−2000%0%FY15FY17FY19FY21FY23FY25
Show the numbers
YearYarrow BioscienceHealthcare median
FY25−4646.1%−30.6%
FY24−7950.9%−47%
FY23−6710.4%−58%
FY22−4865.8%−80.4%
FY21−7876.4%−71.8%
FY20-−62.2%
FY19-−46.2%
FY18-−49.6%
FY17−634.6%−45.9%
FY16−2087.2%−36%
FY15-−37.8%
FY14-−35.5%